

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. – 33. (Cancelled)

34. (Previously Presented) A pharmaceutical compositions, wherein said pharmaceutical composition comprises ginseng fraction CVT-E002 and a pharmaceutically acceptable carrier.

35. (Previously Presented) A method of preparing a pharmaceutical composition suitable for treating a condition characterized by low immunity, wherein said method comprises combining an effective amount of ginseng fraction CVT-E002 and, optionally, an effective amount of another medicament that is suitable for treating a condition characterized by low immunity with at least one pharmaceutically acceptable excipient to produce a pharmaceutical composition suitable for treating a condition characterized by low immunity.

36. (Previously Presented) The method of claim 35, wherein the condition is selected from the group consisting of common cold, influenza, chronic fatigue syndrome, AIDS and cancer.

37. (Currently Amended) A method of stimulating the production of IL-1, IL- 46 6 and/or TNF- α in cells, wherein said method comprises contacting said cells with an effective amount of ginseng fraction CVT-E002.

38. (Cancelled)

39. (Previously Presented) A method of activating B-lymphocyte proliferation and antibody production resulting from said B-lymphocyte proliferation in a patient in

need of such proliferation, wherein said method comprises administering to the patient an effective amount of ginseng fraction CVT-E002.

40. (Previously Presented) A method of treating a condition characterized by low immunity in a patient in need thereof, comprising administering to the patient an effective amount of ginseng fraction CVT-E002.

41. (Original) The method of claim 40, wherein the condition is selected from the group consisting of common cold, influenza, chronic fatigue syndrome, AIDS and cancer.

42. (Previously Presented) A method of stimulating the *in vitro* production of immunoglobulins in cells, wherein said method comprises contacting cells with an effective amount of ginseng fraction CVT-E002.

43. (Previously Presented) A method of stimulating the *in vivo* production of immunoglobulins in a subject in need thereof, wherein said method comprises administering to the subject an effective amount of ginseng fraction CVT-E002.